Kazia Therapeutics Ltd SEC filings KZIA
Kazia Therapeutics Ltd has 1,000 filings in SEC EDGAR's recent list, going back to May 1, 2007. Its latest annual report, Form 20-F, was filed on Nov 7, 2025 for the period ended Jun 30, 2025. The most recent current report (Form 6-K) was filed on Sep 22, 2026. The company's fiscal year ends on June 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| NT 20-F | Filing | Nov 2, 2026 | Jun 30, 2026 |
| EFFECT | Filing | Mar 27, 2026 | — |
| CORRESP | Letter to the SEC | Mar 26, 2026 | — |
| UPLOAD | Letter from the SEC | Mar 25, 2026 | — |
| EFFECT | Filing | Dec 23, 2025 | — |
| EFFECT | Filing | Dec 23, 2025 | — |
| EFFECT | Filing | Dec 22, 2025 | — |
| EFFECT | Filing | Dec 22, 2025 | — |
| CORRESP | Letter to the SEC | Dec 22, 2025 | — |
| CORRESP | Letter to the SEC | Dec 22, 2025 | — |
| D | Filing | Dec 18, 2025 | — |
| NT 20-F | Filing | Oct 31, 2025 | Jun 30, 2025 |
| D | Filing | Aug 14, 2025 | — |
| EFFECT | Filing | Feb 5, 2025 | — |
| CORRESP | Letter to the SEC | Feb 3, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 31, 2025 | — |
| D | Filing | Jan 17, 2025 | — |
| EFFECT | Filing | Dec 2, 2024 | — |
| EFFECT | Filing | Dec 2, 2024 | — |
| NT 20-F | Filing | Nov 1, 2024 | Jun 30, 2024 |
| EFFECT | Filing | Sep 12, 2024 | — |
| CORRESP | Letter to the SEC | Sep 10, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 9, 2024 | — |
| EFFECT | Filing | Jun 28, 2024 | — |
| CORRESP | Letter to the SEC | Jun 26, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 26, 2024 | — |
| EFFECT | Filing | Jun 4, 2024 | — |
| CORRESP | Letter to the SEC | May 31, 2024 | — |
| UPLOAD | Letter from the SEC | May 31, 2024 | — |
| EFFECT | Filing | Feb 5, 2024 | — |
| CORRESP | Letter to the SEC | Feb 2, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 1, 2024 | — |
| EFFECT | Filing | Dec 22, 2023 | — |
| CORRESP | Letter to the SEC | Dec 21, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 20, 2023 | — |
| D | Filing | Dec 15, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 28, 2022 | — |
| CORRESP | Letter to the SEC | Apr 20, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 22, 2022 | — |
| EFFECT | Filing | Sep 8, 2021 | — |
| CORRESP | Letter to the SEC | Sep 7, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 3, 2021 | — |
| EFFECT | Filing | Aug 30, 2018 | — |
| CORRESP | Letter to the SEC | Aug 29, 2018 | — |
| CORRESP | Letter to the SEC | Aug 23, 2018 | — |
| UPLOAD | Letter from the SEC | Jul 24, 2018 | — |
| CT ORDER | Filing | Feb 8, 2018 | — |
| EFFECT | Filing | Sep 24, 2015 | — |
| CORRESP | Letter to the SEC | Sep 16, 2015 | — |
| UPLOAD | Letter from the SEC | Jul 23, 2015 | — |
| EFFECT | Filing | Mar 17, 2015 | — |
| UPLOAD | Letter from the SEC | Jul 17, 2013 | — |
| CORRESP | Letter to the SEC | Jun 10, 2013 | — |
| UPLOAD | Letter from the SEC | May 23, 2013 | — |
| CORRESP | Letter to the SEC | Apr 26, 2013 | — |
| CORRESP | Letter to the SEC | Apr 16, 2013 | — |
| UPLOAD | Letter from the SEC | Mar 29, 2013 | — |
| CORRESP | Letter to the SEC | Mar 7, 2013 | — |
| UPLOAD | Letter from the SEC | Feb 14, 2013 | — |
| UPLOAD | Letter from the SEC | Jun 17, 2010 | — |
| CORRESP | Letter to the SEC | May 13, 2010 | — |
| UPLOAD | Letter from the SEC | Apr 29, 2010 | — |
| CORRESP | Letter to the SEC | Apr 15, 2010 | — |
| UPLOAD | Letter from the SEC | Apr 8, 2010 | — |
| UPLOAD | Letter from the SEC | May 28, 2009 | — |
| CT ORDER | Filing | May 28, 2009 | — |
| CORRESP | Letter to the SEC | May 5, 2009 | — |
| UPLOAD | Letter from the SEC | Apr 23, 2009 | — |
| CORRESP | Letter to the SEC | Mar 20, 2009 | — |
| CORRESP | Letter to the SEC | Feb 27, 2009 | — |
| UPLOAD | Letter from the SEC | Feb 24, 2009 | — |
| UPLOAD | Letter from the SEC | Jul 31, 2008 | — |
| UPLOAD | Letter from the SEC | Jul 10, 2008 | — |
| CORRESP | Letter to the SEC | Jun 13, 2008 | — |
| UPLOAD | Letter from the SEC | May 28, 2008 | — |
| CORRESP | Letter to the SEC | May 14, 2008 | — |
| CORRESP | Letter to the SEC | May 2, 2008 | — |
| CORRESP | Letter to the SEC | Apr 18, 2008 | — |
Showing 78 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KZIA (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- Australia
- Headquarters
- Sydney Nsw
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1075880
- Former names
- NOVOGEN LTD (until Nov 17, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.